Advanced Search

Technical Analysis for SWTX - SpringWorks Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 28.9 4.75% 1.31
SWTX closed up 4.75 percent on Friday, December 13, 2019, on 1.79 times normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
See historical SWTX trend table...
Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Calm After Storm Range Contraction 4.75%
Upper Bollinger Band Walk Strength 4.75%
Inside Day Range Contraction 4.75%
Wide Bands Range Expansion 4.75%
Overbought Stochastic Strength 4.75%
Slingshot Bullish Bullish Swing Setup 3.92%
Wide Range Bar Range Expansion 3.92%
Older signals for SWTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
SWTX Chart by TradingView
Basic chart:

Profile

Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Biotechnology Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Pharmacy Drug Development

Is SWTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Dec 13 We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Dec 10 The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
Dec 9 Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (AS...
Dec 4 Raymond James likes Zimmer Biomet in premarket analyst action
Nov 20 Village Farms International leads consumer gainers; Crown Crafts only loser
Nov 13 The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Nov 12 SpringWorks Therapeutics EPS misses by $1.29
Nov 12 SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Oct 24 SpringWorks launches mid-stage study of mirdametinib in nerve tumors
Oct 24 SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)
See more SWTX news...

Indicators

Indicator Value
52 Week High 30.42
52 Week Low 17.02
Average Volume 121,579
200-Day Moving Average 0.00
50-Day Moving Average 21.00
20-Day Moving Average 23.59
10-Day Moving Average 26.70
Average True Range 2.29
ADX 29.61
+DI 30.95
-DI 13.49
Chandelier Exit (Long, 3 ATRs ) 23.54
Chandelier Exit (Short, 3 ATRs ) 24.18
Upper Bollinger Band 30.52
Lower Bollinger Band 16.67
Percent B (%b) 0.88
BandWidth 58.66
MACD Line 2.22
MACD Signal Line 1.63
MACD Histogram 0.5823
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.21
Resistance 3 (R3) 33.04 31.43 32.50
Resistance 2 (R2) 31.43 30.33 31.52 32.26
Resistance 1 (R1) 30.17 29.65 30.80 30.34 32.02
Pivot Point 28.55 28.55 28.87 28.64 28.55
Support 1 (S1) 27.29 27.46 27.92 27.46 25.78
Support 2 (S2) 25.68 26.78 25.77 25.54
Support 3 (S3) 24.41 25.68 25.31
Support 4 (S4) 24.59